{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:15:52Z","timestamp":1789193752548,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cytokine release syndrome (CRS) is a severe complication following Chimeric Antigen Receptor T-cell (CAR-T) therapy, characterized by an excessive inflammatory response triggered by the activation of CAR-T cells. Clinically, approaches like tocilizumab and corticosteroids are commonly used to treat CRS. However, those methods might be insufficient, particularly in treating severe CRS patients (grade 3-4). Nowadays, therapeutic plasma exchange (PE) has been used as a promising adjunctive therapy to treat severe CRS, as it can rapidly remove circulating inflammatory cytokines and immune complexes which contribute to CRS progression. To summarize the characteristics and clinical usage of PE, we provide the experiences of 3 PE cases from our institution and 19 PE cases from relevant literature. In this review, we concluded that PE is effective in reducing elevated serum cytokine levels and alleviating CRS symptoms such as fever, hypotension, and neurotoxicity. Furthermore, we discuss the principles and development of PE and compare CAR-T-induced CRS with CRS caused by viral infections. In addition, PE demonstrates clear advantages over other blood purification techniques including hemofiltration (HF) and hemodiafiltration (HDF), particularly in its ability to remove large-molecular cytokines and immune complexes. To conclude, PE presents a promising therapeutic approach for managing severe CRS after CAR-T therapy, especially when standard treatments have failed.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1597512","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:22:15Z","timestamp":1750742535000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Utilizing plasma exchange for severe cytokine release syndrome after CAR-T cell therapy: clinical experience and literature insights"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiasi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dali","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingqin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangnian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic Malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1448709","article-title":"The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"biomark Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B16","doi-asserted-by":"publisher","first-page":"111761","DOI":"10.1016\/j.intimp.2024.111761","article-title":"Multi-centers experience using therapeutic plasma exchange for corticosteroid\/tocilizumab-refractory cytokine release syndrome following CAR-T therapy","volume":"130","author":"Pu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/1078-0432.CCR-18-1379","article-title":"Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-T cell infusion: A case report","volume":"25","author":"Xiao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1339","article-title":"Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed\/refractory acute lymphoblastic leukemia","volume":"26","author":"Heng","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2018.181.issue-3","article-title":"Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB","volume":"181","author":"Li","year":"2018","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.1013933","article-title":"New insight into neurological degeneration: Inflammatory cytokines and blood-brain barrier","volume":"15","author":"Yang","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.13303\/j.cjbt.issn.1004-549x.2022.06.019","article-title":"Chimeric antigen receptor T-associated cytokines release syndrome managed by therapeutic plasma exchange and tumor necrosis factor inhibitors: a case report","volume":"35","author":"Lu Zhang","year":"2022","journal-title":"Chin J Blood Transfusion"},{"key":"B22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J Clin Apher"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21560","article-title":"Perfect storm: Therapeutic plasma exchange for a patient with thyroid storm","volume":"33","author":"McGonigle","year":"2018","journal-title":"J Clin Apher"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e22154","DOI":"10.1002\/jca.22154","article-title":"Therapeutic plasma exchange management for a pediatric patient presenting with immune thrombotic thrombocytopenic purpura in a setting of common variable immunodeficiency","volume":"39","author":"Budhipramono","year":"2024","journal-title":"J Clin Apher"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/000992288001900710","article-title":"Treatment of Goodpasture\u2019s syndrome with plasma exchange and immunosuppression","volume":"19","author":"Siegler","year":"1980","journal-title":"Clin Pediatr (Phila)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)93089-0","article-title":"Immunosuppression and plasma-exchange in the treatment of Goodpasture\u2019s syndrome","volume":"1","author":"Lockwood","year":"1976","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.11.029","article-title":"The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial","volume":"107","author":"Odler","year":"2024","journal-title":"Kidney Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"108448","DOI":"10.1016\/j.clim.2020.108448","article-title":"COVID-19: Immunology and treatment options","volume":"215","author":"Felsenstein","year":"2020","journal-title":"Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"103433","DOI":"10.1016\/j.transci.2022.103433","article-title":"Role of therapeutic plasma exchange in the management of COVID-19-induced cytokine storm syndrome","volume":"61","author":"Beraud","year":"2022","journal-title":"Transfus Apher Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.07.016","article-title":"Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome","volume":"119","author":"Faqihi","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"B32","doi-asserted-by":"publisher","first-page":"156287","DOI":"10.1016\/j.cyto.2023.156287","article-title":"Emerging aspects of cytokine storm in COVID-19: The role of proinflammatory cytokines and therapeutic prospects","volume":"169","author":"Dharra","year":"2023","journal-title":"Cytokine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"m1091","DOI":"10.1136\/bmj.m1091","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e31802b9575","article-title":"Continuous hemofiltration in hyperthermic septic shock patients","volume":"63","author":"Pesta\u00f1a","year":"2007","journal-title":"J\u00a0Trauma"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10047-017-0991-4","article-title":"Efficacy of hemofiltration with PEPA membrane for IL-6 removal in a rat sepsis model","volume":"20","author":"Maeda","year":"2017","journal-title":"J Artif Organs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000243","article-title":"Hemofiltration successfully eliminates severe cytokine release syndrome following CD19 CAR-T-cell therapy","volume":"41","author":"Liu","year":"2018","journal-title":"J Immunother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13613-019-0530-y","article-title":"Cytokine removal in human septic shock: Where are we and where are we going","volume":"9","author":"Honore","year":"2019","journal-title":"Ann Intensive Care"},{"key":"B38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1053\/j.ajkd.2016.02.049","article-title":"High-dose versus\u00a0conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury: A randomized controlled trial","volume":"68","author":"Park","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.37757\/MR2012V14.N3.5","article-title":"Continuous venovenous hemodiafiltration in patients with multiple organ dysfunction syndrome in an intensive care unit","volume":"14","author":"Cuza","year":"2012","journal-title":"MEDICC Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering10020145","article-title":"Hemodiafiltration: technical and medical insights","volume":"10","author":"Lang","year":"2023","journal-title":"Bioengineering (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-6-199909210-00011","article-title":"Therapeutic plasma exchange: an update from the Canadian Apheresis Group","volume":"131","author":"Clark","year":"1999","journal-title":"Ann\u00a0Intern Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1597512\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:22:16Z","timestamp":1750742536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1597512\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1597512"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1597512","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"article-number":"1597512"}}